MedTrace Logo

Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma

NCT06464861 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2025-02-07

No results posted yet for this study

Summary

To study the safety and efficacy of cord blood-derived CD19 CAR-NK cells sequential with 7x19 CAR-T in relapse / refractory B cell lymphoma

Conditions

  • Primary Mediastinal B-cell Lymphoma (PMBCL)
  • Mantle Cell Lymphoma (MCL)
  • Diffuse Large B Cell Lymphoma( DLBCL)

Interventions

BIOLOGICAL

CD19-CAR-NK/T

Cord blood derived CD19 CARNK sequential Treatment with 7x19 CAR-T

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • Wenbin Wenbin, Professor · Zhejiang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-20
Primary Completion
2026-06-30
Completion
2027-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06464861 on ClinicalTrials.gov